Novo Nordisk to Acquire Dicerna


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
Pharma news update 29/11/2021

Dicerna Pharmaceuticals, Inc. announced that it has entered into a definitive agreement with Novo Nordisk under which Novo Nordisk will acquire Dicerna, a biopharmaceutical company focused on the development of investigational ribonucleic acid interference (RNAi) therapeutics, for $38.25 per share in cash, which represents a total equity value of $3.3 billion and a premium of 80% to Dicerna’s closing price on November 17, 2021. The transaction was unanimously approved by the Dicerna Board of Directors and the Board of Directors of Novo Nordisk.

Novo Nordisk and Dicerna have been parties to a research collaboration since 2019 to discover and develop RNAi therapies using Dicerna’s proprietary GalXC™ RNAi platform technology. The collaboration between Novo Nordisk and Dicerna encompassed the exploration of more than 30 liver cell targets with the potential to deliver multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases. Novo Nordisk expects to initiate clinical development of the first investigational RNAi therapeutic to emerge from this collaboration in 2022.

Dicerna’s RNAi technology platform enables access to intracellular disease targets across hepatic and extrahepatic cell and tissue types, complementing Novo Nordisk’s existing technology platforms. This acquisition supports Novo Nordisk’s strategy of developing and applying a broad range of technology platforms across all Novo Nordisk therapeutic areas.

“The acquisition of Dicerna accelerates Novo Nordisk’s research within RNAi and expands the usage of the RNAi technology,” said Marcus Schindler, Executive Vice President and Chief Scientific Officer of Novo Nordisk. “We build on our successful collaboration and by combining Dicerna’s state-of-the-art RNAi drug engine and intracellular delivery with our deep capabilities in disease biology understanding and tissue targeting through peptides and proteins we have the potential to expand our pipeline and deliver life-changing precision medicines for people living with chronic diseases such as diabetes, obesity, cardiovascular disease and NASH, as well as rare diseases like endocrine disorders and bleeding disorders.”

“Since the start of our collaboration two years ago, the Dicerna and Novo Nordisk teams have established a strong rapport built on a foundation of mutual respect for one another’s capabilities, culture and expertise,” said Douglas Fambrough, Ph.D., Founder, President and Chief Executive Officer of Dicerna. “The combination of Dicerna’s expertise in RNAi and oligonucleotide therapeutics and highly skilled employees with Novo Nordisk’s industry leadership in developing and commercializing medicines to treat serious chronic diseases has the potential to significantly accelerate and expand our mission to deliver GalXC RNAi therapies for the benefit of patients and all our stakeholders.”

Tags : #NovoNordisk #Dicerna #RnaiPlatform #MarcusSchindler

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

University of Birmingham Dubai invites applications for MSc in Financial Data ScienceJuly 08, 2025
Benefits of ShirodharaJuly 07, 2025
WIKA India Launches “Re-Inventing Hygiene” Campaign to Advance Standards in Food & Pharma InstrumentationJuly 07, 2025
Cambodia is 2nd Asian country to rollout long-acting injectable HIV prevention optionJuly 07, 2025
Wheels of Care: How Tele-MRVs Are Reaching Mothers Left BehindJuly 07, 2025
Personalized Psychiatry's Developing Use of PharmacogenomicsJuly 07, 2025
Honourable Ministers Shri Anil Kumar Bachoo and Shri Palanivel Thiaga Rajan Open IIRSI 2025 Convention on Intraocular Implant & Refractive SurgeryJuly 05, 2025
A 69-year-old retired teacher gives a lesson of life by donating multiple organsJuly 05, 2025
Silent Scans, Smarter Eyes: Inside India’s First AI Teleradiology HubsJuly 05, 2025
Can You Hear Me Now? The Quiet Revolution of Tele-Audiology in Rural Childhood CareJuly 05, 2025
What’s on Their Plate? Uncovering Malnutrition Through Midday Meal DataJuly 05, 2025
Can Diabetics Conquer Space? The Mission That’s Changing Medicine on Earth and BeyondJuly 05, 2025
Center for Diagnostics and Telemedicine Celebrates Graduation of First Masters in Medical Artificial IntelligenceJuly 04, 2025
Sightsavers India Fellowship Programme Invites Applications for 2025July 04, 2025
After 4 Surgeries & 15kg Abdominal Tumour, 61-YO Reclaims Life In Marathon Operation At HCGMCCJuly 04, 2025
The DNA Warning: Are Genomic Screening Camps the Early Alarm We Need?July 04, 2025
Ticked, Tapped, and Forgotten? The Truth About Digital Consent FormsJuly 04, 2025
Evaluating the Impact of AI Chatbots in Mental Health Support for College StudentsJuly 04, 2025
Integrating Oral Health with Primary Care: Pilot Programs in Rural MaharashtraJuly 04, 2025
Will governments firewall public health from tobacco industry's lies and deceptive tactics?July 03, 2025